PDE10A and Huntington disease: Taken together, this body of work suggests that PDE10A levels in patients with HD are prominently and progressively reduced through disease progression and might be primarily linked to the phenotypic manifestations, which is also supported, as discussed in more detail later, by the identification of loss‐of‐function PED10A mutations causing chorea in humans.52